2023
Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018)
Shahrir S, Crothers K, McGinnis K, Chan K, Baeten J, Wilson S, Butt A, Pisani M, Baldassarri S, Justice A, Williams E. Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018). Open Forum Infectious Diseases 2023, 10: ofad089. PMID: 36968969, PMCID: PMC10034589, DOI: 10.1093/ofid/ofad089.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyAging Cohort StudyHuman immunodeficiency virusCessation medicationsCohort studyCurrent smokersCurrent smokingHIV statusImmunodeficiency virusRelative riskHuman immunodeficiency virus statusSmoking cessation medicationsNicotine replacement therapyRates of receiptDangers of smokingOutpatient prescriptionsReplacement therapyPharmacy dataVirus statusTobacco useAnnual rateMedicationsSmokingPWHStatistical difference
2020
Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementReceipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV
Shahrir S, Crothers K, McGinnis KA, Chan KCG, Baeten JM, Wilson SM, Butt AA, Pisani MA, Baldassarri SR, Justice A, Williams EC. Receipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV. Progress In Cardiovascular Diseases 2020, 63: 118-124. PMID: 31987807, PMCID: PMC7251937, DOI: 10.1016/j.pcad.2020.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsCardiovascular DiseasesFemaleHealth StatusHIV InfectionsHIV Long-Term SurvivorsHumansLongitudinal StudiesMaleMiddle AgedPreventive Health ServicesProspective StudiesProtective FactorsRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokersSmokingSmoking CessationSmoking Cessation AgentsTime FactorsTreatment OutcomeUnited StatesVeterans HealthViral LoadConceptsNicotine replacement therapyVeterans Aging Cohort StudyMultivariable log-linear regression modelsPotential treatment disparitiesSmoking cessation pharmacotherapyPatient-level factorsAging Cohort StudyMental health disordersRates of receiptUninfected participantsUninfected patientsCardiovascular riskCessation pharmacotherapyCohort studyCurrent smokingHIV statusMultivariable analysisTreatment disparitiesReplacement therapyRelative riskHealth disordersPharmacotherapyPLWHSmokingHIV
2010
Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients
Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, Bravata DM, Goldstein LB. Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients. Circulation Cardiovascular Quality And Outcomes 2010, 4: 30-38. PMID: 21098780, PMCID: PMC3073519, DOI: 10.1161/circoutcomes.109.850883.Peer-Reviewed Original ResearchConceptsDeep vein thrombosis prophylaxisElderly ischemic stroke patientsIschemic stroke patientsThrombosis prophylaxisAntithrombotic medicationSkilled nursing facilitiesEligible patientsAntithrombotic therapyIschemic strokeAtrial fibrillationStroke patientsNursing facilitiesPatients ages 85 yearsSecondary stroke preventionAge 85 yearsRates of receiptLow treatment ratesRate of treatmentAntiplatelet medicationsStroke preventionEffect of agePatient agePatient characteristicsAntiplatelet drugsMedicare fee
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply